Welcome to our dedicated page for Protalix Biother SEC filings (Ticker: PLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Protalix BioTherapeutics, Inc. (PLX) provides access to the company’s official U.S. Securities and Exchange Commission disclosures. As a NYSE American–listed biopharmaceutical issuer focused on rare disease therapeutics and recombinant proteins produced via its ProCellEx® plant cell-based system, Protalix uses these filings to report material events, financial results, governance decisions and capital markets activities.
Investors can review Form 8-K filings that Protalix has used to announce quarterly financial and business results, clinical and regulatory updates for products such as Elfabrio® and PRX–115, changes in executive leadership, entry into or amendments of material agreements, and outcomes of legal or stockholder matters. Other SEC reports, including annual and quarterly reports, provide detailed discussions of revenue from sales of Elfabrio and Elelyso®, collaboration structures with partners like Chiesi, Pfizer and Fiocruz, and the status of development programs such as PRX–119.
For those monitoring corporate finance and ownership, this page also surfaces filings related to equity offerings and governance, such as amendments to at-the-market offering agreements and disclosures about stockholder meetings and executive compensation arrangements. Together, these documents help explain how Protalix funds its operations, manages risk and aligns management incentives.
Stock Titan enhances this information with AI-powered summaries that highlight key points from lengthy SEC documents, helping readers quickly understand the implications of Protalix’s 10-K and 10-Q reports, 8-K current reports and other submissions. Real-time updates from EDGAR ensure that new filings appear promptly, while structured access to transaction-related disclosures and governance items supports deeper due diligence on PLX.
Naos Yaron, Sr. VP, Operations of Protalix BioTherapeutics (PLX), reported transactions dated 09/03/2025. He was awarded 25,000 restricted shares under the company's Amended and Restated 2006 Stock Incentive Plan, which vest in 12 equal quarterly installments and accelerate on a corporate transaction or change in control. The shares are registered in the name of a trustee to comply with Israeli tax rules.
On the same date he was granted a stock option to buy 50,000 shares at $1.64 per share exercisable through 09/03/2035 with a similar 12-quarter vesting schedule. The Form 4 also reports a sale of 7,112 shares and shows 225,817 shares beneficially owned following the transactions (held indirectly by a trust).
Protalix BioTherapeutics (PLX) reporting person Dror Bashan, who is President, CEO and a director, recorded equity awards and a disposition on 09/03/2025. He was granted 195,000 restricted shares under the company’s amended 2006 Stock Incentive Plan that vest in 12 equal quarterly installments and are registered in a trustee for Israeli tax purposes. The filing also shows a grant of a stock option covering 340,000 shares with a $1.64 exercise price, exercisable immediately and expiring 09/03/2035, and a reported disposition of 132,516 common shares. The restricted shares and options include accelerated vesting on a corporate transaction or change in control as described in the Plan.
Protalix BioTherapeutics (PLX) Form 3: Gilad Mamlok, Sr. VP and CFO, filed an initial Form 3 reporting derivative securities on 08/24/2025. The filing shows a stock option exercisable beginning 07/20/2035 covering 597,990 shares of common stock at an exercise price of $1.45 per share. The option is held directly and vests in 12 equal quarterly installments commencing on the grant date, with accelerated vesting provisions upon a corporate transaction or change in control under the company’s amended 2006 Stock Incentive Plan. The form is signed by Gilad Mamlok on 08/25/2025.
Protalix BioTherapeutics, Inc. entered into a new letter agreement on August 22, 2025 amending its existing at-the-market equity offering program with H.C. Wainwright & Co., LLC. The change updates the prior sales agreement so that future at-the-market sales of common stock can be made under Protalix’s new shelf registration statement on Form S-3 (Registration No. 333-286802).
The company also filed as exhibits the amendment itself and a legal opinion from its counsel, Mayer Brown LLP, confirming the legality of the shares that may be sold under this updated program.
Protalix BioTherapeutics (PLX) filed a prospectus supplement for potential offerings of equity, preferred stock, debt securities and warrants. The document emphasizes numerous risk factors including commercialization risks for its approved product Elfabrio (pegunigalsidase alfa-iwxj), which carries an FDA boxed warning; potential operational disruptions from regional hostilities in Israel and related supply-chain and regulatory impacts; and counterparty risks such as Fiocruz’s compliance with a supply and technology transfer agreement.
The prospectus also details standard offering mechanics to be disclosed per series (pricing, interest, redemption, conversion, covenants and events of default), reserved shares under its stock plan (7,130,994 exercisable options at $1.80 and up to 4,410,713 additional reserved shares), and SEC documents incorporated by reference including the 2024 Annual Report and several 2025 quarterly and current reports.
Protalix BioTherapeutics filed a pre-effective amendment to its Form S-3 as an exhibits-only filing to include an updated auditor consent from Kesselman & Kesselman (a PwC Israel member firm). The amendment consists solely of the facing page, an explanatory note, Item 16 with the exhibit index, the signature page and the filed exhibits; the prospectus is unchanged and has been omitted. The filing includes signatures by Dror Bashan and other officers and directors.
Protalix BioTherapeutics (PLX) reported consolidated revenue of $25.8 million for the six months ended June 30, 2025, up from $17.2 million a year earlier, driven by product sales to Pfizer, Fiocruz and Chiesi. The company narrowed its six-month net loss to $3.5 million from $6.8 million a year ago and recorded a $0.16 million net income in the three months ended June 30, 2025. Cash and cash equivalents were $17.9 million with short-term bank deposits of $15.5 million, total assets of $78.5 million and stockholders' equity of $49.9 million.
The company generated $6.8 million net proceeds from at-the-market sales under the Sales Agreement during the six-month period and stated that cash and short-term deposits are sufficient to satisfy capital needs for at least 12 months. Commercial activities include marketed products Elfabrio and Elelyso with commercialization partners Chiesi and Pfizer, ongoing clinical programs (PRX-115, PRX-119) and manufacturing responsibilities for approved products. The filing also discloses potential operational exposure to the Israel conflict and steps taken to mitigate supply risk.
Protalix BioTherapeutics, Inc. disclosed that it furnished a press release announcing its financial results for the fiscal quarter ended June 30, 2025 and provided a business and clinical update. The press release is furnished as Exhibit 99.1 to the Current Report on Form 8-K. The filing notes that the furnished information is not deemed "filed" under Section 18 of the Exchange Act and, therefore, is not incorporated by reference into registration statements or other filings unless specifically stated.
Protalix BioTherapeutics director Aharon Schwartz purchased 129,000 shares of Protalix (PLX) common stock on 06/10/2025 at a weighted average price of $1.596 per share, with execution prices ranging from $1.575 to $1.60 across multiple trades. Following the reported purchase, the reporting person beneficially owned 303,000 shares.
The filing identifies Mr. Schwartz as a director and shows the transaction coded as a purchase. The report notes the transaction was executed in multiple trades and that the reporting person will provide full trade-by-trade details upon request to the SEC staff, the issuer, or a security holder.